Ultragenyx Pharmaceutical Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$1.53B
↑+1.9% +$29Mvs FY2024
Total Liabilities
$1.60B
↑+29.3% +$364Mvs FY2024
Cash
$421M
↑+142.0% +$247Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.53B | $1.50B |
| Current Assets | $951M | $817M |
| Cash | $421M | $174M |
| ST Investments | $0 | $0 |
| Receivables | $158M | $122M |
| Inventory | $52M | $45M |
| Other Current | $320M | $476M |
| Non-Current Assets | $581M | $686M |
| PPE | $244M | $266M |
| Goodwill | $44M | $44M |
| Intangibles | $176M | $178M |
| Investments | $0 | $0 |
| Other Non-Current | $117M | $198M |
| Total Liab+Eq | $1.52B | $1.50B |
| Current Liab. | $384M | $344M |
| Accounts Payable | $31M | $39M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $353M | $305M |
| Non-Current Liab. | $1.22B | $897M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $1.22B | $897M |
| Equity | $-80M | $255M |
| Retained Earnings | $4.53B | $3.96B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · RARE · Comparing FY2025 vs FY2024